Yama A Abassi
Overview
Explore the profile of Yama A Abassi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang X, Aggarwal P, Broeckel U, Abassi Y
J Pharmacol Toxicol Methods
. 2023 Jul;
123:107282.
PMID: 37419294
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) present an attractive in vitro platform to model safety and toxicity assessments-notably screening pro-arrhythmic compounds. The utility of the platform is stymied by...
2.
Robinson P, Sparrow A, Psaras Y, Steeples V, Simon J, Broyles C, et al.
J Mol Cell Cardiol
. 2023 May;
180:44-57.
PMID: 37127261
We compared commonly used BAPTA-derived chemical Ca dyes (fura2, Fluo-4, and Rhod-2) with a newer genetically encoded indicator (R-GECO) in single cell models of the heart. We assessed their performance...
3.
Xi B, Berahovich R, Zhou H, Xu S, Wei Y, Guan J, et al.
J Vis Exp
. 2019 Dec;
(153).
PMID: 31789308
Chimeric antigen receptor (CAR) T-cell therapy for cancer has achieved significant clinical benefit for resistant and refractory hematological malignancies such as childhood acute lymphocytic leukemia. Efforts are currently underway to...
4.
Millard D, Dang Q, Shi H, Zhang X, Strock C, Kraushaar U, et al.
Toxicol Sci
. 2018 May;
164(2):550-562.
PMID: 29718449
Recent in vitro cardiac safety studies demonstrate the ability of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to detect electrophysiologic effects of drugs. However, variability contributed by unique approaches, procedures,...
5.
Cerignoli F, Abassi Y, Lamarche B, Guenther G, Santa Ana D, Guimet D, et al.
PLoS One
. 2018 Mar;
13(3):e0193498.
PMID: 29499048
A growing understanding of the molecular interactions between immune effector cells and target tumor cells, coupled with refined gene therapy approaches, are giving rise to novel cancer immunotherapeutics with remarkable...
6.
Lange S, Gehmlich K, Lun A, Blondelle J, Hooper C, Dalton N, et al.
Nat Commun
. 2016 Jun;
7:12120.
PMID: 27353086
MLP (muscle LIM protein)-deficient mice count among the first mouse models for dilated cardiomyopathy (DCM), yet the exact role of MLP in cardiac signalling processes is still enigmatic. Elevated PKCα...
7.
Zhang X, Guo L, Zeng H, White S, Furniss M, Balasubramanian B, et al.
J Pharmacol Toxicol Methods
. 2016 Jun;
81:201-16.
PMID: 27282640
Introduction: The ICH S7B guidelines recommend that all new chemical entities should be subjected to hERG repolarization screening due to its association with life-threatening "Torsades de Pointes" (TdP) arrhythmia. However,...
8.
Ke N, Nguyen K, Irelan J, Abassi Y
Methods Mol Biol
. 2015 Jan;
1272:215-26.
PMID: 25563187
GPCRs constitute one of the most sought-after targets in drug discovery because they are associated with conditions ranging from cardiovascular diseases, autoimmune diseases, inflammation, cancer, and diseases of the nervous...
9.
Scott C, Zhang X, Abi-Gerges N, Lamore S, Abassi Y, Peters M
Toxicol Sci
. 2014 Sep;
142(2):331-8.
PMID: 25237062
Cardiovascular toxicity, a prominent reason for late-stage failures in drug development, has resulted in a demand for in vitro assays that can predict this liability in early drug discovery. Current...
10.
Rotroff D, Dix D, Houck K, Kavlock R, Knudsen T, Martin M, et al.
Chem Res Toxicol
. 2013 May;
26(7):1097-107.
PMID: 23682706
High-throughput screening (HTS) assays capable of profiling thousands of environmentally relevant chemicals for in vitro biological activity provide useful information on the potential for disrupting endocrine pathways. Disruption of the...